Literature DB >> 22801753

How to demonstrate the reversibility of end-organ function before implantation of left ventricular assist device in INTERMACS profile 2 patients?

Teruhiko Imamura1, Koichiro Kinugawa, Taro Shiga, Naoko Kato, Miyoko Endo, Toshiro Inaba, Hisataka Maki, Masaru Hatano, Atsushi Yao, Yasunobu Hirata, Masaaki Akahane, Takashi Nishimura, Shunei Kyo, Minoru Ono, Ryozo Nagai.   

Abstract

For the time being, in Japan, two recently approved implantable ventricular assist devices (VADs) are indicated only when a patient has been listed for heart transplantation or approved to be eligible for heart transplantation by in-hospital committee. The reversibility of end-organ dysfunction must be expected before VAD implantation, but it is often hard to prove during worsening clinical status. We report two patients whose end-organ dysfunction had been eventually demonstrated to be reversible by invasive procedures such as transluminal liver biopsy or transient insertion of intra-aortic balloon pumping.

Entities:  

Mesh:

Year:  2012        PMID: 22801753     DOI: 10.1007/s10047-012-0654-4

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  22 in total

1.  Is liver fibrosis reversible?

Authors:  P A Bonis; S L Friedman; M M Kaplan
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

2.  Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation.

Authors:  A J Bank; S H Mir; D Q Nguyen; R M Bolman; S J Shumway; L W Miller; D R Kaiser; S M Ormaza; S J Park
Journal:  Ann Thorac Surg       Date:  2000-05       Impact factor: 4.330

3.  The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011.

Authors:  Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2011-10       Impact factor: 10.247

4.  Third INTERMACS Annual Report: the evolution of destination therapy in the United States.

Authors:  James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; Karen L Ulisney; J Timothy Baldwin; James B Young
Journal:  J Heart Lung Transplant       Date:  2011-02       Impact factor: 10.247

5.  Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device.

Authors:  Stuart D Russell; Joseph G Rogers; Carmelo A Milano; David B Dyke; Francis D Pagani; Juan M Aranda; Charles T Klodell; Andrew J Boyle; Ranjit John; Leway Chen; H Todd Massey; David J Farrar; John V Conte
Journal:  Circulation       Date:  2009-11-23       Impact factor: 29.690

Review 6.  How to treat stage D heart failure? - When to implant left ventricular assist devices in the era of continuous flow pumps?-.

Authors:  Koichiro Kinugawa
Journal:  Circ J       Date:  2011-08-02       Impact factor: 2.993

7.  Guidelines for the referral and management of patients eligible for solid organ transplantation.

Authors:  T I Steinman; B N Becker; A E Frost; K M Olthoff; F W Smart; W N Suki; A H Wilkinson
Journal:  Transplantation       Date:  2001-05-15       Impact factor: 4.939

8.  Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients.

Authors:  Mark A Perazella; Steven G Coca; Mehmet Kanbay; Ursula C Brewster; Chirag R Parikh
Journal:  Clin J Am Soc Nephrol       Date:  2008-09-10       Impact factor: 8.237

9.  Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial.

Authors:  Joseph G Rogers; Javed Butler; Steven L Lansman; Alan Gass; Peer M Portner; Michael K Pasque; Richard N Pierson
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

10.  Importance of preoperative liver function as a predictor of survival in patients supported with Thoratec ventricular assist devices as a bridge to transplantation.

Authors:  O Reinhartz; D J Farrar; J H Hershon; G J Avery; E A Haeusslein; J D Hill
Journal:  J Thorac Cardiovasc Surg       Date:  1998-10       Impact factor: 5.209

View more
  2 in total

Review 1.  Current status of extracorporeal ventricular assist devices in Japan.

Authors:  Takashi Nishimura
Journal:  J Artif Organs       Date:  2014-06-22       Impact factor: 1.731

2.  Increased serum Wisteria floribunda agglutinin positive Mac-2 binding protein (Mac-2 binding protein glycosylation isomer) in chronic heart failure: a pilot study.

Authors:  Atsushi Okada; Hideaki Kanzaki; Yasuhiro Hamatani; Seiji Takashio; Hiroyuki Takahama; Makoto Amaki; Takuya Hasegawa; Yasuo Sugano; Satoshi Yasuda; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2017-11-02       Impact factor: 2.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.